RJFSA
MRTX

Raymond James Financial Services Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,409
Closed -$255K – 2881
2018
Q3 		$255K Sell
5,409
-810
-13% -$45.1K ﹤0.01% 2376
2018
Q2 		$307K Sell
6,219
-1,343
-18% -$50.7K ﹤0.01% 2214
2018
Q1 		$232K Sell
7,562
-3,764
-33% -$104K ﹤0.01% 2170
2017
Q4 		$207K Buy
+11,326
New +$176K ﹤0.01% 2247

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Raymond James Financial Services Advisors's MRTX Position: Q4 2018 in Review

Raymond James Financial Services Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2018, closing a stake of 5,409 shares — an estimated $255K sold.

Raymond James Financial Services Advisors first reported a position in MRTX in Q4 2017 and held it in 4 quarters. The position peaked at $307K in Q2 2018. 112 funds tracked by Wall St. Rank hold MRTX as of Q4 2018.

  • Raymond James Financial Services Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 5,409 Mirati Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $255K.
  • Raymond James Financial Services Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2017 and held it in 4 quarters.
  • Raymond James Financial Services Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $307K in Q2 2018.
  • 112 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2018, filed 11 Feb 2019.